Lobe Sciences Reports First Quarter 2026 Results and Highlights

Executive Summary

• Lobe Sciences reported unaudited Q1 FY‑2026 results, showing cash of $5.99 M and a net loss of $1.31 M.
• R&D expenses rose to $982k (up from $7.6k YoY) as the company advanced its lead program L‑130 (psilocin mucate) and early‑stage S‑100 candidate.
• The firm highlighted continued preclinical/clinical progress, added scientific staff, and reiterated its value‑creation strategy while maintaining a fiscally conservative stance.

Key Details

• Cash & Liquidity: $5,991,614 cash; $1,025,098 short‑term investments; net working capital $4,047,891 as of 30 Nov 2025.
• R&D Expenditure: $982,087 for the quarter (vs. $7,551 in Q1 2025), driven by preclinical studies and regulatory work on L‑130.
• Operating Cash Flow: cash used in operating activities $579,006 (up from $243,068 YoY).
• Net Loss: $1,305,827 for the quarter (vs. $800,634 YoY).
• Program Updates – Cynaptec (64% owned):
• L‑130 advanced through preclinical studies, IND‑enabling work, and Phase 1a trial in healthy volunteers completed outside the U.S.; ongoing FDA Pre‑IND interactions.
• Additional strategic review of opioid use disorder indication.
• Program Updates – Altemia (100% owned):
• S‑100 (sickle cell disease) continued early‑stage development; proprietary lipid‑based delivery platform described.
• Limited commercialization pilot for a medical food targeting nutritional deficiencies in sickle‑cell patients, focusing on reimbursement pathways in Georgia.
• Corporate Actions: Added scientific personnel to support Phase 1/2 progression; maintained tight cash controls while scaling R&D activity.
• Strategic Outlook: Emphasis on value‑creation through asset advancement and selective evaluation of additional opportunities; expects strengthened working capital to reduce liquidity risk.

Notable Quotes

“During the first quarter of fiscal 2026, Lobe meaningfully accelerated its research and development activities… This progress reflects our transformative approach to drug development of next‑generation serotonergic agents…” – Dr. Fred Sancilio, CEO

Materiality Assessment: Material – Negative (significant loss disclosed and material program updates).